Background and Aims The Canadian Registry of Synagis® (CARESS) tracks palivizumab utilization and respiratory syncytial virus (RSV) hospitalizations in high-risk infants including 186 with cystic fibrosis (CF). This study compares respiratory illness (RI) and RSV positive hospitalization (RSVH) rates in CF infants versus:
those with other underlying medical disorders (MD) and
those who meet standard indications for RSV prophylaxis (SD).
Methods A prospective, observational registry of infants from 30 sites who received ≥1 dose of palivizumab during the 2005–2011 RSV seasons. Palivizumab utilization and RI outcomes were collected monthly over each individual season.
Results 10,452 infants were enrolled (CF: 186, 1.8%; MD: 1378, 13.2%; SD: 8888, 85.0%). There were significant differences (p<0.05) between the three groups in gestational and enrolment ages, weight at birth and at enrolment and proportions of: Caucasians, siblings, multiple births, daycare attendance, smokers in the household, >5 people in the household, immediate family history of atopy, and complexity of neonatal course. Infants with CF had a lower RI hospitalization rate than the MD (4.3% versus 11.0%, p=0.003) but not the SD group (5.8%, p=0.522). For RSVH rate, CF infants were not significantly different from the MD (0.72% versus 2.46%, p=0.227) or SD (1.49%, p=0.999) groups. In the Cox proportional analysis, hazard ratios of time to first RSVH in CF were similar to MD (p=0.272) and SD infants (p=0.422).
Conclusions This is the largest report of CF infants who have received palivizumab world-wide. Despite RI rate differences, RSVH rates appear similar to those in MD and SD.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.